Superior Progression-Free Survival Associated with Continuous Targeted Therapy Combination for BRAF-mutated Melanoma

Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.

Read more

Rutgers Supplies Hospitals with PPE to Battle COVID-19

During the coronavirus pandemic, health care professionals worldwide are facing shortages of personal protection equipment (PPE). But faculty, students and staff from across Rutgers are coming together to produce face shields and intubation boxes themselves with off-the-shelf materials to help relieve the PPE shortage at area hospitals.

Read more

Rutgers Cancer Institute Offers Clinical Trial Examining Potential Treatment for COVID-19

Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.

Read more

Zimmerli Art Museum Offers Virtual Tours, Demonstrations in Response to COVID-19

In response to coronavirus quarantines in New Jersey and nationwide, Zimmerli Art Museum at Rutgers–New Brunswick is taking steps to provide children and adults with online demonstrations, virtual tours and activities to keep the community productive during this period of uncertainty.

Read more